ArticleCell death & disease2026
CDX2 confers ferroptosis resistance in stage II-III colon cancer via upregulation of NUPR1.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NUPR1 in breast cancer: mechanisms and potential applications.Frontiers in physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
High CDX2 expression frequently indicates better survival in stage II-III colon cancer; nevertheless, it is linked to decreased systemic chemotherapy response rates. Ferroptosis, commonly recognized as an iron-dependent oxidative death, is increasingly believed as a disease-modifying mechanism. The purpose of this study is to determine the role of ferroptosis in CDX2-mediated colon cancer chemical resistance. Mechanistically, CDX2-mediated NUPR1 transcription prevents ferroptotic cell death by reducing iron accumulation and oxidative stress damage. Depletion of NUPR1 counteracted the effect of CDX2 overexpression in terms of ferroptosis resistance, whereas transfection-enforced re-expression of NUPR1 restores ferroptosis resistance in CDX2-deficient cells. Genetic or pharmacological blockage of CDX2-NUPR1 axis improved the potential of ferroptosis agonists to combat colon cancer in preclinical mouse models. Our study uncovered a novel molecular mechanism by which CDX2 imparts ferroptosis resistance to colon cancer. Blockage of NUPR1 might be as a potential therapeutic strategy for CDX2-positive stage II-III colon cancer. The current study demonstrated a positive correlation between CDX2 expression and chemical resistance in colon cancer. Mechanistically, CDX2 directly transactivates NUPR1 and subsequent its target LCN2 to confer ferroptosis resistance by inhibiting iron-induced oxidative damage. Genetic or pharmacological blockage of CDX2-NUPR1 axis may strengthen the anticancer efficacy of adjuvant chemotherapy on stage II-III CDX2-positive colon cancer in vitro and in vivo. Our study uncovered a novel molecular mechanism by which CDX2 confers ferroptosis resistance in colon cancer. Blockage of NUPR1 might be as a potential therapeutic strategy for stage II-III CDX2-positive colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.